Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From Korea

BACKGROUND: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder characterized by uncontrolled terminal complement activation. Eculizumab, a monoclonal antibody C5 inhibitor was introduced in Korea in 2009 and has been the standard treatment option for PNH. METHODS: This study as...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jin Seok, Jang, Jun Ho, Jo, Deog-Yeon, Ahn, Seo-Yeon, Yoon, Sung-Soo, Lee, Je-Hwan, Kim, Sung-Hyun, Choi, Chul Won, Shin, Ho-Jin, Kim, Min-Kyoung, Lee, Jae Hoon, Mun, Yeung-Chul, Kong, Jee Hyun, Hyun, BokJin, Nam, HyunSun, Kim, Eunhye, Kwak, Min Joo, Won, Yong Kyun, Lee, Jong Wook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10593597/
https://www.ncbi.nlm.nih.gov/pubmed/37873628
http://dx.doi.org/10.3346/jkms.2023.38.e328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10593597/
https://www.ncbi.nlm.nih.gov/pubmed/37873628
http://dx.doi.org/10.3346/jkms.2023.38.e328

Ejemplares similares